The challenge with rapidly diagnosing sepsis – a potentially life-threatening medical condition triggered by blood-borne pathogens – stems from the fact that measuring only one biomarker often does not allow a clear-cut diagnosis. Now, a multi-disciplinary team at Harvard's Wyss Institute for Biologically Inspired Engineering and the University of Bath, United Kingdom, has further developed the Institute's eRapid technology as an affinity-based, low-cost electrochemical diagnostic sensor platform for the detection of multiple clinically relevant biomarkers in whole blood. The device uses a novel graphene nanocomposite-based surface coating and was demonstrated to accurately detect three different sepsis biomarkers simultaneously.
An official website of the United States government.